Skip to main content
Top
Published in: Cardiovascular Diabetology 1/2010

Open Access 01-12-2010 | Original investigation

Associations of Fetuin-A levels with vascular disease in type 2 diabetes patients with early diabetic nephropathy

Authors: Marcel Roos, Dimitrios Oikonomou, Maximilian von Eynatten, Peter B Luppa, Uwe Heemann, Jens Lutz, Marcus Baumann, Peter P Nawroth, Angelika Bierhaus, Per M Humpert

Published in: Cardiovascular Diabetology | Issue 1/2010

Login to get access

Abstract

Background

Ambigous results exist on fetuin-A as marker for vascular disease in type 2 diabetes. This study aims to define the role of fetuin-A as marker for micro- and macrovascular disease in a high risk population of patients with type 2 diabetes mellitus and early diabetic nephropathy.

Methods

Fetuin-A serum levels were assessed by ELISA in a cross-sectional setting in 153 patients with type 2 diabetes. Associations of fetuin-A with metabolic, inflammatory and vascular markers were studied. Atherosclerotic burden was assessed by ankle-brachial-index (ABI) as well as detection of common carotid artery intima-media thickness (IMT).

Results

Levels of fetuin-A were lower in male than in female patients (0.49 ± 0.15 vs. 0.56 ± 0.20 g/L, p = 0.02). In addition, there was an inverse correlation with age (r = -0.20, P = 0.01). Bivariate correlations adjusted for age and gender revealed no significant correlations with metabolic parameters, except for a weak inverse correlation with serum adiponectin (r = -0.19, p = 0.02). Regarding parameters of micro- and macrovascular disease, fetuin-A was significantly associated with ABI (r = 0.18, p = 0.04), while there was no association with IMT (r = -0.07, p = n.s). Patients with an ABI < 0.9 had lower fetuin A levels than patients with an ABI 0.9-1.3 or > 1.3 (0.43 ± 0.10 vs. 0.52 ± 0.17 vs. 0.54 ± 0.18 g/L p = 0.05). Neither GFR nor albuminuria were associated with fetuin-A serum levels. Patients with prevalent neuropathy did not have altered fetuin-A levels compared to diabetic controls. In step-wise logistic regression analysis including age, gender, HbA1c, total cholesterol, glomerular filtration rate and fetuin-A, only total cholesterol (β = 0.01, p = 0.02) and fetuin-A (β = -5.99, p = 0.03) proved to be independent predictors of an ABI < 0.9.

Conclusions

The results of this cross-sectional study suggest that lower fetuin-A levels are associated with macrovascular late complications in high-risk type 2 diabetes patients while there are no associations of fetuin-A with metabolic status or microvascular complications.
Appendix
Available only for authorised users
Literature
1.
go back to reference St Clair L, Ballantyne CM: Biological surrogates for enhancing cardiovascular risk prediction in type 2 diabetes mellitus. Am J Cardiol. 2007, 99: 80B-88B. 10.1016/j.amjcard.2006.11.008.CrossRefPubMed St Clair L, Ballantyne CM: Biological surrogates for enhancing cardiovascular risk prediction in type 2 diabetes mellitus. Am J Cardiol. 2007, 99: 80B-88B. 10.1016/j.amjcard.2006.11.008.CrossRefPubMed
2.
go back to reference Zethelius B, Berglund L, Sundström J, Ingelsson E, Basu S, Larsson A, Venge P, Arnlöv J: Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med. 2008, 358: 2107-2116. 10.1056/NEJMoa0707064.CrossRefPubMed Zethelius B, Berglund L, Sundström J, Ingelsson E, Basu S, Larsson A, Venge P, Arnlöv J: Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med. 2008, 358: 2107-2116. 10.1056/NEJMoa0707064.CrossRefPubMed
3.
go back to reference Folsom AR, Chambless LE, Ballantyne CM, Coresh J, Heiss G, Wu KK, Boerwinkle E, Mosley TH, Sorlie P, Diao G, Sharrett AR: An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the atherosclerosis risk in communities study. Arch Intern Med. 2006, 166: 1368-1373. 10.1001/archinte.166.13.1368.CrossRefPubMed Folsom AR, Chambless LE, Ballantyne CM, Coresh J, Heiss G, Wu KK, Boerwinkle E, Mosley TH, Sorlie P, Diao G, Sharrett AR: An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the atherosclerosis risk in communities study. Arch Intern Med. 2006, 166: 1368-1373. 10.1001/archinte.166.13.1368.CrossRefPubMed
4.
go back to reference Kim HC, Greenland P, Rossouw JE, Manson JE, Cochrane BB, Lasser NL, Limacher MC, Lloyd-Jones DM, Margolis KL, Robinson JG: Multimarker prediction of coronary heart disease risk: the Women's Health Initiative. J Am Coll Cardiol. 2010, 55: 2080-2091. 10.1016/j.jacc.2009.12.047.CrossRefPubMed Kim HC, Greenland P, Rossouw JE, Manson JE, Cochrane BB, Lasser NL, Limacher MC, Lloyd-Jones DM, Margolis KL, Robinson JG: Multimarker prediction of coronary heart disease risk: the Women's Health Initiative. J Am Coll Cardiol. 2010, 55: 2080-2091. 10.1016/j.jacc.2009.12.047.CrossRefPubMed
5.
go back to reference Heiss A, DuChesne A, Denecke B, Grötzinger J, Yamamoto K, Renné T, Jahnen-Dechent W: Structural basis of calcification inhibition by alpha 2-HS glycoprotein/fetuin A. Formation of colloidal calciprotein particles. J Biol Chem. 2003, 278: 13333-13341. 10.1074/jbc.M210868200.CrossRefPubMed Heiss A, DuChesne A, Denecke B, Grötzinger J, Yamamoto K, Renné T, Jahnen-Dechent W: Structural basis of calcification inhibition by alpha 2-HS glycoprotein/fetuin A. Formation of colloidal calciprotein particles. J Biol Chem. 2003, 278: 13333-13341. 10.1074/jbc.M210868200.CrossRefPubMed
6.
go back to reference Schafer C, Heiss A, Schwarz A, Westenfeld R, Ketteler M, Floege J, Muller-Esterl W, Schinke T, Jahnen-Dechent W: The serum protein alpha 2-Heremans-Schmid glyco-protein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest. 2003, 112: 357-366.PubMedCentralCrossRefPubMed Schafer C, Heiss A, Schwarz A, Westenfeld R, Ketteler M, Floege J, Muller-Esterl W, Schinke T, Jahnen-Dechent W: The serum protein alpha 2-Heremans-Schmid glyco-protein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest. 2003, 112: 357-366.PubMedCentralCrossRefPubMed
7.
go back to reference Luo G, Ducy P, McKee MD, Pinero GJ, Loyer E, Behringer RR, Karsenty G: Spontaneous cal-cification of arteries and cartilage in mice lacking matrix GLA protein. Nature. 1997, 386: 78-81. 10.1038/386078a0.CrossRefPubMed Luo G, Ducy P, McKee MD, Pinero GJ, Loyer E, Behringer RR, Karsenty G: Spontaneous cal-cification of arteries and cartilage in mice lacking matrix GLA protein. Nature. 1997, 386: 78-81. 10.1038/386078a0.CrossRefPubMed
8.
go back to reference Hermans MM, Brandenburg V, Ketteler M, Kooman JP, van der Sande FM, Boeschoten EW, Leunissen KM, Krediet RT, Dekker FW: Netherlands cooperative study on the adequacy of Dialysis (NECOSAD). Association of serum fetuin-A levels with mortality in dialysis patients. Kidney Int. 2007, 72: 202-207. 10.1038/sj.ki.5002178.CrossRefPubMed Hermans MM, Brandenburg V, Ketteler M, Kooman JP, van der Sande FM, Boeschoten EW, Leunissen KM, Krediet RT, Dekker FW: Netherlands cooperative study on the adequacy of Dialysis (NECOSAD). Association of serum fetuin-A levels with mortality in dialysis patients. Kidney Int. 2007, 72: 202-207. 10.1038/sj.ki.5002178.CrossRefPubMed
9.
go back to reference Ketteler M, Bongartz P, Westenfeld R, Wildberger JE, Mahnken AH, Böhm R, Metzger T, Wan-ner C, Jahnen-Dechent W, Floege J: Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet. 2003, 361: 827-833. 10.1016/S0140-6736(03)12710-9.CrossRefPubMed Ketteler M, Bongartz P, Westenfeld R, Wildberger JE, Mahnken AH, Böhm R, Metzger T, Wan-ner C, Jahnen-Dechent W, Floege J: Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet. 2003, 361: 827-833. 10.1016/S0140-6736(03)12710-9.CrossRefPubMed
10.
go back to reference Weikert C, Stefan N, Schulze MB, Pischon T, Berger K, Joost HG, Häring HU, Boeing H, Fritsche A: Plasma fetuin-A levels and the risk of myocardial infarction and ischemic stroke. Circulation. 2008, 118: 2555-2562. 10.1161/CIRCULATIONAHA.108.814418.CrossRefPubMed Weikert C, Stefan N, Schulze MB, Pischon T, Berger K, Joost HG, Häring HU, Boeing H, Fritsche A: Plasma fetuin-A levels and the risk of myocardial infarction and ischemic stroke. Circulation. 2008, 118: 2555-2562. 10.1161/CIRCULATIONAHA.108.814418.CrossRefPubMed
11.
go back to reference Roos M, von Eynatten M, Heemann U, Rothenbacher D, Brenner H, Breitling LP: Serum Fetuin-A, Cardiovascular Risk Factors and 6-year Follow-up Outcome in Patients With Coronary Heart Disease. Am J Cardiol. 2010, 105: 1666-1672. 10.1016/j.amjcard.2010.01.342.CrossRefPubMed Roos M, von Eynatten M, Heemann U, Rothenbacher D, Brenner H, Breitling LP: Serum Fetuin-A, Cardiovascular Risk Factors and 6-year Follow-up Outcome in Patients With Coronary Heart Disease. Am J Cardiol. 2010, 105: 1666-1672. 10.1016/j.amjcard.2010.01.342.CrossRefPubMed
12.
go back to reference Eraso LH, Ginwala N, Qasim AN, Mehta NN, Dlugash R, Kapoor S, Schwartz S, Schutta M, Iqbal N, Mohler ER, Reilly MP: Association of Lower Plasma Fetuin-A Levels With Peripheral Arterial Disease in Type 2 Diabetes. Diabetes Care. 2010, 33: 408-410. 10.2337/dc09-1541.PubMedCentralCrossRefPubMed Eraso LH, Ginwala N, Qasim AN, Mehta NN, Dlugash R, Kapoor S, Schwartz S, Schutta M, Iqbal N, Mohler ER, Reilly MP: Association of Lower Plasma Fetuin-A Levels With Peripheral Arterial Disease in Type 2 Diabetes. Diabetes Care. 2010, 33: 408-410. 10.2337/dc09-1541.PubMedCentralCrossRefPubMed
13.
go back to reference Emoto M, Mori K, Lee E, Kawano N, Yamazaki Y, Tsuchikura S, Morioka T, Koyama H, Shoji T, Inaba M, Nishizawa Y: Fetuin-A and atheroclerotic calcified plaque in patients with type 2 diabetes mellitus. Metabolism. 2010, 59: 873-878. 10.1016/j.metabol.2009.10.005.CrossRefPubMed Emoto M, Mori K, Lee E, Kawano N, Yamazaki Y, Tsuchikura S, Morioka T, Koyama H, Shoji T, Inaba M, Nishizawa Y: Fetuin-A and atheroclerotic calcified plaque in patients with type 2 diabetes mellitus. Metabolism. 2010, 59: 873-878. 10.1016/j.metabol.2009.10.005.CrossRefPubMed
14.
go back to reference Stefan N, Weikert C, Ix JH, Fritsche A, Häring HU: Association of lower plasma fetuin-A levels with peripheral arterial disease in type 2 diabetes: response to Eraso et al. Diabetes Care. 2010, 33: e55-10.2337/dc10-0002. author reply e56CrossRefPubMed Stefan N, Weikert C, Ix JH, Fritsche A, Häring HU: Association of lower plasma fetuin-A levels with peripheral arterial disease in type 2 diabetes: response to Eraso et al. Diabetes Care. 2010, 33: e55-10.2337/dc10-0002. author reply e56CrossRefPubMed
15.
go back to reference Mehrotra R, Westenfeld R, Christenson P, Budoff M, Ipp E, Takasu J, Gupta A, Norris K, Ketteler M, Adler S: Serum fetuin-A in nondialyzed patients with diabetic nephropathy: relationship with coronary artery calcification. Kidney Int. 1995, 67: 1070-1077. 10.1111/j.1523-1755.2005.00172.x.CrossRef Mehrotra R, Westenfeld R, Christenson P, Budoff M, Ipp E, Takasu J, Gupta A, Norris K, Ketteler M, Adler S: Serum fetuin-A in nondialyzed patients with diabetic nephropathy: relationship with coronary artery calcification. Kidney Int. 1995, 67: 1070-1077. 10.1111/j.1523-1755.2005.00172.x.CrossRef
16.
go back to reference Gross JL, de Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T: Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care. 2005, 28: 164-76. 10.2337/diacare.28.1.164. ReviewCrossRefPubMed Gross JL, de Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T: Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care. 2005, 28: 164-76. 10.2337/diacare.28.1.164. ReviewCrossRefPubMed
17.
go back to reference von Eynatten M, Baumann M, Heemann U, Zdunek D, Hess G, Nawroth PP, Bierhaus A, Humpert PM: Urinary L-FABP and anaemia: distinct roles of urinary markers in type 2 diabetes. Eur J Clin Invest. 2010, 40: 95-102. 10.1111/j.1365-2362.2009.02220.x.CrossRefPubMed von Eynatten M, Baumann M, Heemann U, Zdunek D, Hess G, Nawroth PP, Bierhaus A, Humpert PM: Urinary L-FABP and anaemia: distinct roles of urinary markers in type 2 diabetes. Eur J Clin Invest. 2010, 40: 95-102. 10.1111/j.1365-2362.2009.02220.x.CrossRefPubMed
18.
go back to reference Levey AS, Coresh J, Greene T, Marsh J, Stevens LA, Kusek JW, Van Lente F: Chronic Kidney Disease Epidemiology Collaboration. Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem. 2007, 53: 766-72. 10.1373/clinchem.2006.077180.CrossRefPubMed Levey AS, Coresh J, Greene T, Marsh J, Stevens LA, Kusek JW, Van Lente F: Chronic Kidney Disease Epidemiology Collaboration. Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem. 2007, 53: 766-72. 10.1373/clinchem.2006.077180.CrossRefPubMed
19.
go back to reference Humpert PM, Papadopoulos G, Schaefer K, Djuric Z, Konrade I, Morcos M, Nawroth PP, Bierhaus A: sRAGE and esRAGE are not associated with peripheral or autonomic neuropathy in type 2 diabetes. Horm Metab Res. 2007, 39: 899-902. 10.1055/s-2007-993155.CrossRefPubMed Humpert PM, Papadopoulos G, Schaefer K, Djuric Z, Konrade I, Morcos M, Nawroth PP, Bierhaus A: sRAGE and esRAGE are not associated with peripheral or autonomic neuropathy in type 2 diabetes. Horm Metab Res. 2007, 39: 899-902. 10.1055/s-2007-993155.CrossRefPubMed
20.
go back to reference Meijer JW, Smit AJ, Lefrandt JD, van der Hoeven JH, Hoogenberg K, Links TP: Back to basics in diagnosing diabetic polyneuropathy with the tuning fork!. Diabetes Care. 2005, 28: 2201-2205. 10.2337/diacare.28.9.2201.CrossRefPubMed Meijer JW, Smit AJ, Lefrandt JD, van der Hoeven JH, Hoogenberg K, Links TP: Back to basics in diagnosing diabetic polyneuropathy with the tuning fork!. Diabetes Care. 2005, 28: 2201-2205. 10.2337/diacare.28.9.2201.CrossRefPubMed
21.
go back to reference Hennige AM, Staiger H, Wicke C, Machicao F, Fritsche A, Häring HU, Stefan N: Fetuin-A induces cytokine expression and suppresses adiponectin production. PLoS One. 2008, 12 (3): e1765-10.1371/journal.pone.0001765.CrossRef Hennige AM, Staiger H, Wicke C, Machicao F, Fritsche A, Häring HU, Stefan N: Fetuin-A induces cytokine expression and suppresses adiponectin production. PLoS One. 2008, 12 (3): e1765-10.1371/journal.pone.0001765.CrossRef
22.
go back to reference Ix JH, Shlipak MG, Brandenburg VM, Ali S, Ketteler M, Whooley MA: Association between human fetuin-A and the metabolic syndrome: data from the Heart and Soul study. Circulation. 2006, 113: 1760-1767. 10.1161/CIRCULATIONAHA.105.588723.PubMedCentralCrossRefPubMed Ix JH, Shlipak MG, Brandenburg VM, Ali S, Ketteler M, Whooley MA: Association between human fetuin-A and the metabolic syndrome: data from the Heart and Soul study. Circulation. 2006, 113: 1760-1767. 10.1161/CIRCULATIONAHA.105.588723.PubMedCentralCrossRefPubMed
23.
go back to reference Stefan N, Fritsche A, Weikert C, Boeing H, Joost HG, Häring HU, Schulze MB: Plasma fetuin-A levels and the risk of type 2 diabetes. Diabetes. 2008, 57: 2762-2767. 10.2337/db08-0538.PubMedCentralCrossRefPubMed Stefan N, Fritsche A, Weikert C, Boeing H, Joost HG, Häring HU, Schulze MB: Plasma fetuin-A levels and the risk of type 2 diabetes. Diabetes. 2008, 57: 2762-2767. 10.2337/db08-0538.PubMedCentralCrossRefPubMed
24.
go back to reference Hayden MR, Tyagi SC, Kolb L, Sowers JR, Khanna R: Vascular ossification - calcification in metabolic syndrome, type 2 diabetes mellitus, chronic kidney disease, and calciphylaxis - calcific uremic arteriolopathy: the emerging role of sodium thiosulfate. Cardiovascular Diabetology. 2005, 4: 4-10.1186/1475-2840-4-4.PubMedCentralCrossRefPubMed Hayden MR, Tyagi SC, Kolb L, Sowers JR, Khanna R: Vascular ossification - calcification in metabolic syndrome, type 2 diabetes mellitus, chronic kidney disease, and calciphylaxis - calcific uremic arteriolopathy: the emerging role of sodium thiosulfate. Cardiovascular Diabetology. 2005, 4: 4-10.1186/1475-2840-4-4.PubMedCentralCrossRefPubMed
25.
go back to reference Baumann M, Richart T, Sollinger D, Pelisek J, Roos M, Kouznetsova T, Eckstein HH, Heemann U, Staessen JA: Association between carotid diameter and the advanced glycation endproduct Nε-Carboxymethyllysine (CML). Cardiovascular Diabetology. 2009, 8: 45-10.1186/1475-2840-8-45.PubMedCentralCrossRefPubMed Baumann M, Richart T, Sollinger D, Pelisek J, Roos M, Kouznetsova T, Eckstein HH, Heemann U, Staessen JA: Association between carotid diameter and the advanced glycation endproduct Nε-Carboxymethyllysine (CML). Cardiovascular Diabetology. 2009, 8: 45-10.1186/1475-2840-8-45.PubMedCentralCrossRefPubMed
26.
go back to reference Merx MW, Schäfer C, Westenfeld R, Brandenburg V, Hidajat S, Weber C, Ketteler M, Jahnen-Dechent W: Myocardial stiffness, cardiac remodeling, and diastolic dysfunction in calcification-prone fetuin-A-deficient mice. J Am Soc Nephrol. 2005, 16: 3357-3364. 10.1681/ASN.2005040365.CrossRefPubMed Merx MW, Schäfer C, Westenfeld R, Brandenburg V, Hidajat S, Weber C, Ketteler M, Jahnen-Dechent W: Myocardial stiffness, cardiac remodeling, and diastolic dysfunction in calcification-prone fetuin-A-deficient mice. J Am Soc Nephrol. 2005, 16: 3357-3364. 10.1681/ASN.2005040365.CrossRefPubMed
27.
go back to reference Ix JH, Wassel CL, Kanaya AM, Vittinghoff E, Johnson KC, Koster A, Cauley JA, Harris TB, Cummings SR, Shlipak MG: Fetuin-A and incident diabetes mellitus in older persons.; Health ABC Study. JAMA. 2008, 300: 182-188. 10.1001/jama.300.2.182.PubMedCentralCrossRefPubMed Ix JH, Wassel CL, Kanaya AM, Vittinghoff E, Johnson KC, Koster A, Cauley JA, Harris TB, Cummings SR, Shlipak MG: Fetuin-A and incident diabetes mellitus in older persons.; Health ABC Study. JAMA. 2008, 300: 182-188. 10.1001/jama.300.2.182.PubMedCentralCrossRefPubMed
28.
go back to reference Rittig K, Thamer C, Haupt A, Machann J, Peter A, Balletshofer B, Fritsche A, Haring HU, Stefan N: High Plasma Fetuin-A is associated with Increased Carotid Intima-media Thickness in a Middle-Aged Population. Atherosclerosis. 2009, 207: 341-342. 10.1016/j.atherosclerosis.2009.05.018.CrossRefPubMed Rittig K, Thamer C, Haupt A, Machann J, Peter A, Balletshofer B, Fritsche A, Haring HU, Stefan N: High Plasma Fetuin-A is associated with Increased Carotid Intima-media Thickness in a Middle-Aged Population. Atherosclerosis. 2009, 207: 341-342. 10.1016/j.atherosclerosis.2009.05.018.CrossRefPubMed
29.
go back to reference Mori K, Ikari Y, Jono S, Emoto M, Shioi A, Koyama H, Shoji T, Ishimura E, Inaba M, Hara K, Nishizawa Y: Fetuin-A is associated with calcified coronary artery disease. Coron Artery Dis. 2010, 21: 281-5. 10.1097/MCA.0b013e32832fe5d5.CrossRefPubMed Mori K, Ikari Y, Jono S, Emoto M, Shioi A, Koyama H, Shoji T, Ishimura E, Inaba M, Hara K, Nishizawa Y: Fetuin-A is associated with calcified coronary artery disease. Coron Artery Dis. 2010, 21: 281-5. 10.1097/MCA.0b013e32832fe5d5.CrossRefPubMed
30.
go back to reference Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, Lowe GD, Pepys MB, Gudnason V: C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004, 350: 1387-1397. 10.1056/NEJMoa032804.CrossRefPubMed Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, Lowe GD, Pepys MB, Gudnason V: C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004, 350: 1387-1397. 10.1056/NEJMoa032804.CrossRefPubMed
31.
go back to reference von Eynatten M, Hamann A, Twardella D, Nawroth PP, Brenner H, Rothenbacher D: Atherogenic dyslipidaemia but not total- and high-molecular weight adiponectin are associated with the prognostic outcome in patients with coronary heart disease. Eur Heart J. 2008, 29: 1307-1315. 10.1093/eurheartj/ehn135.CrossRefPubMed von Eynatten M, Hamann A, Twardella D, Nawroth PP, Brenner H, Rothenbacher D: Atherogenic dyslipidaemia but not total- and high-molecular weight adiponectin are associated with the prognostic outcome in patients with coronary heart disease. Eur Heart J. 2008, 29: 1307-1315. 10.1093/eurheartj/ehn135.CrossRefPubMed
Metadata
Title
Associations of Fetuin-A levels with vascular disease in type 2 diabetes patients with early diabetic nephropathy
Authors
Marcel Roos
Dimitrios Oikonomou
Maximilian von Eynatten
Peter B Luppa
Uwe Heemann
Jens Lutz
Marcus Baumann
Peter P Nawroth
Angelika Bierhaus
Per M Humpert
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2010
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/1475-2840-9-48

Other articles of this Issue 1/2010

Cardiovascular Diabetology 1/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine